US FDA moves to fast-track psychedelic drugs after Trump order
Published on April 24, 2026.
The U.S. Food and Human Services Administration is moving forward with steps to develop new treatments for serious mental illness. This follows an executive order signed by President Donald Trump that encourages more research into ibogaine. The agency is taking steps to ensure that these treatments are developed quickly.
Related Articles
PG&E CEO Patti Poppe talks about monthly bills, reliability and more
PG&E CEO Patti Poppe discusses customer bills, reliability, and the impact of smarter work on electricity systems to meet growing demands from tech giants.
Letters: Sanford development should proceed
The Sanford city commission's $4 million payout to a developer for allegedly delaying a development, highlighting the need for better understanding and support for families with rare diseases.
‘This is a huge finding’: UCSD researchers work on way to prevent Alzheimer’s disease with molecular ‘switch’
UC San Diego researchers are investigating a potential molecular switch to prevent Alzheimer’s disease, potentially inpatiently and potentially in humans.